Table 7.
BRAF positive | BRAF negative | pa | |
---|---|---|---|
Age | |||
<45 | 7 (25%) | 5 (62.5%) | 0.086 |
>45 | 21 (75%) | 3 (37.5%) | |
Gender | |||
Male | 11 (39%) | 1 (12.5%) | 0.2 |
Female | 17 (61%) | 7 (87.5%) | |
Primary tumor size | |||
≤1.5 cm | 12 (43%) | 4 (50%) | 1 |
>1.5 cm | 16 (57%) | 4 (50%) | |
PTC subtypes | |||
Tall cell (n=14) | 14 (50%) | 0 | 0.01b |
Classical (n=19) | 13 (46%) | 6 (75%) | |
Infiltrative FVPTC (n=2) | 0 | 2 (25%) | |
Microcarcinoma, infiltrative (n=1) | 1 (4%) | 0 | |
No. of positive nodes | |||
≤3 | 10 (36%) | 1 (12.5%) | 0.388 |
>3 | 18 (64%) | 7 (87.5%) | |
Extra-nodal extension (n=34)c | |||
Yes | 10 (37%) | 2 (40%) | 1 |
No | 17 (63%) | 5 (60%) | |
Size of largest positive node (n=35)d | |||
≤1 cm | 14 (51%) | 1 (14%) | 0.1 |
>1 cm | 13 (49%) | 7 (86%) | |
Size of largest metastatic focus (n=35)d | |||
≤1 cm | 15 (56%) | 2 (25%) | 0.2 |
>1 cm | 12 (44%) | 6 (75%) | |
Vascular invasion | |||
Present | 0 | 1 (12.5%) | 0.22 |
Absent | 28 (100%) | 7 (87.5%) | |
ETE | |||
Extensive | 18 (64%) | 4 (50%) | 0.6 |
Focal | 2 (7%) | 3 (37.5%) | |
None | 8 (29%) | 1 (12.5%) |
Fisher's exact test.
Tall cell vs. nontall cell.
In 2 cases, extra nodal extension could not be evaluated.
In one individual, the size of the metastatic node and largest metastatic focus could not be assessed.